ERCC6L in human cancers: oncogenic functions, molecular mechanisms, and clinical implications as a prognostic biomarker and therapeutic target - Poll - MDSpire

ERCC6L in human cancers: oncogenic functions, molecular mechanisms, and clinical implications as a prognostic biomarker and therapeutic target

  • By

  • Lingyu Jiang

  • Huaihai Zhou

  • Jing He

  • Junqi Qin

  • Jianwei Huang

  • Jiaping Wei

  • Yifan Zhou

  • Yonglong Zhong

  • July 1, 2026

  • 0 min

Share

Original Source(s)

ERCC6L in human cancers: oncogenic functions, molecular mechanisms, and clinical implications as a prognostic biomarker and therapeutic target

  • by Lingyu Jiang, Huaihai Zhou, Jing He, Junqi Qin, Jianwei Huang, Jiaping Wei, Yifan Zhou, Yonglong Zhong

  • July 1, 2026

Related Content

Metabolic sovereignty through oxidative hostility: a mechanistic perspective on how cancer engineers stromal dependency via ROS-mediated lysosomal reprogramming

Correction: Olaparib-mediated enhancement of 5-fluorouracil cytotoxicity in mismatch repair deficient colorectal cancer cells

Ferroptosis in chemotherapy resistance and resensitization in breast cancer: a systematic review of preclinical evidence and translational implications